Keros Therapeutics, Inc. - Common Stock (KROS) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2020 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
KROS on Nasdaq
Shares outstanding
30,507,100
Price per share
$19.50
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
12,944,968
Total reported value
$263,387,126
% of total 13F portfolios
0%
Share change
-3,856,470
Value change
-$66,423,350
Number of holders
103
Price from insider filings
$19.50
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Keros Therapeutics, Inc. - Common Stock (KROS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Madison Avenue Partners, LP 6.4% $37,150,652 2,614,402 Madison Avenue Partners, LP 07 May 2025
TANG CAPITAL MANAGEMENT LLC 7.9% $38,268,569 2,418,984 TANG CAPITAL MANAGEMENT, LLC 15 Oct 2025
ExodusPoint Capital Management, LP 6.3% $28,675,722 1,907,899 ExodusPoint Capital Management, LP 10 Nov 2025
D. E. SHAW & CO, L.P. 5.1% $24,457,052 1,545,948 D. E. Shaw & Co., L.P. 20 Oct 2025
VANGUARD GROUP INC 5% -22% $31,056,075 -$21,193,964 1,525,355 -41% The Vanguard Group 31 Dec 2025
ALKEON CAPITAL MANAGEMENT LLC 2.7% $15,645,210 1,101,000 Alkeon Capital Management LLC 31 Dec 2024
FMR LLC 1.7% $10,010,547 704,472 FMR LLC 31 Jan 2025
JPMORGAN CHASE & CO 0.2% -102% $1,617,141 -$35,146,204 113,803 -96% JPMORGAN CHASE & CO. 30 Apr 2025

As of 31 Dec 2025, 103 institutional investors reported holding 12,944,968 shares of Keros Therapeutics, Inc. - Common Stock (KROS). This represents 42% of the company’s total 30,507,100 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Keros Therapeutics, Inc. - Common Stock (KROS) together control 40% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 7.5% 2,290,532 -16% 0% $46,635,220
VANGUARD GROUP INC 5% 1,525,355 -44% 0% $31,056,228
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 4.4% 1,334,516 +416% 0.02% $27,170,746
STATE STREET CORP 3.5% 1,075,993 -17% 0% $21,907,217
JACOBS LEVY EQUITY MANAGEMENT, INC 2.5% 768,425 +27% 0.06% $15,645,133
FEDERATED HERMES, INC. 2.1% 654,724 +27% 0.02% $13,330,180
GEODE CAPITAL MANAGEMENT, LLC 2.1% 635,208 -24% 0% $12,935,496
RENAISSANCE TECHNOLOGIES LLC 1.9% 591,686 +282% 0.02% $12,046,727
GOLDMAN SACHS GROUP INC 1.9% 590,517 -55% 0% $12,022,926
Nantahala Capital Management, LLC 1.2% 360,419 -71% 0.44% $7,338,131
Connor, Clark & Lunn Investment Management Ltd. 1.1% 321,346 -4.1% 0.02% $6,542,605
HRT FINANCIAL LP 0.86% 260,891 +510% 0.02% $5,311,000
MORGAN STANLEY 0.76% 230,492 -42% 0% $4,692,833
DEUTSCHE BANK AG\ 0.64% 195,281 +740% 0% $3,975,921
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.61% 186,779 -36% 0% $3,802,820
JANE STREET GROUP, LLC 0.53% 162,009 -0.27% 0% $3,298,504
BESSEMER GROUP INC 0.47% 143,853 0% $2,929,000
PANAGORA ASSET MANAGEMENT INC 0.4% 122,821 +303% 0.01% $2,500,636
Bank of New York Mellon Corp 0.4% 121,582 +9.6% 0% $2,475,410
Y-Intercept (Hong Kong) Ltd 0.38% 117,361 +142% 0.05% $2,389,470
SG Americas Securities, LLC 0.32% 98,703 +1421% 0% $2,010,000
UBS Group AG 0.32% 97,084 -6.5% 0% $1,976,631
BARCLAYS PLC 0.24% 74,726 -25% 0% $1,521,421
Nuveen, LLC 0.21% 63,097 -17% 0% $1,284,655
Empowered Funds, LLC 0.2% 60,078 0.01% $1,223,188

Institutional Holders of Keros Therapeutics, Inc. - Common Stock (KROS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 12,944,968 $263,387,126 -$66,423,350 $20.36 103
2025 Q3 35,272,212 $558,014,186 -$7,638,925 $15.82 151
2025 Q2 35,922,272 $479,567,957 +$53,894,426 $13.35 134
2025 Q1 32,796,190 $334,208,916 -$101,548,195 $10.19 154
2024 Q4 36,741,918 $581,640,265 -$99,583,348 $15.83 159
2024 Q3 34,948,467 $2,029,993,469 +$197,656,348 $58.07 162
2024 Q2 31,483,081 $1,437,735,495 -$1,704,535 $45.70 150
2024 Q1 31,378,208 $2,077,197,760 +$376,189,592 $66.20 144
2023 Q4 25,748,679 $1,023,986,857 +$107,389,201 $39.76 119
2023 Q3 22,915,590 $730,562,303 +$10,983,703 $31.88 106
2023 Q2 22,423,232 $900,980,099 +$13,493,306 $40.18 121
2023 Q1 22,003,238 $936,983,921 +$94,494,039 $42.70 128
2022 Q4 19,814,952 $951,517,038 +$88,887,412 $48.02 122
2022 Q3 18,166,429 $683,394,048 +$33,259,877 $37.62 107
2022 Q2 17,360,328 $479,673,115 +$10,253,619 $27.63 101
2022 Q1 16,425,972 $892,979,574 +$13,785,386 $54.38 101
2021 Q4 16,155,340 $944,400,680 +$68,408,989 $58.51 96
2021 Q3 13,732,777 $543,300,250 -$15,835,150 $39.56 86
2021 Q2 14,120,390 $599,680,759 -$43,588,395 $42.47 79
2021 Q1 14,412,080 $887,014,019 -$122,639,102 $61.55 83
2020 Q4 16,029,747 $1,129,296,879 +$301,336,670 $70.54 81
2020 Q3 11,780,724 $454,579,430 +$33,779,230 $38.57 49
2020 Q2 10,926,163 $409,790,602 +$409,790,602 $37.51 51